ENDRA Life Sciences, Inc. NDRAW 深 滬
等待開盤 09-03 09:30:00 美东时间
0.03
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.03
- 總市值 124.92万
- 52周最高 0.72
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.01
- 委 比 0.00%
- 總股本 4164.02万
- 歷史最高 2.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.01
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ENDRA Life Sciences Q2 EPS $(1.71) Beats $(2.27) Estimate
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(1.71) per share which beat the analyst consensus estimate of $(2.27) by 24.67 percent. This is a 2037.5 percent decrease over losses of $(0.08) per share
08-15 04:17
快讯 | ENDRA生命科学公司第二季度运营支出为120万美元
ENDRA Life Sciences Q2 Operating Expenses USD 1.2 Million
08-15 04:05
ENDRA Life Sciences Launches Bitcoin Treasury Strategy, Forms Advisory Board With James Altucher, James Manning, And Rayne Steinberg
The Board of Directors (the "Board") of ENDRA Life Sciences Inc. (the "Company") has authorized the Company to develop and pursue a cryptocurrency treasury strategy. Following this authorization, the Company has:
07-23 21:08
ENDRA Life Sciences Expects Q2 2025 Loss Of ~$1.3M, No Revenue, And ~$2.6M In Total Assets
Recent Financial ResultsBelow is a summary of certain preliminary estimates regarding our financial results for the quarter ended June 30, 2025. This preliminary financial information is based upon our estimates and is
07-10 04:55
快讯 | ENDRA Life Sciences Inc - 预计2025年第二季度没有营业收入 - SEC文件
ENDRA Life Sciences Inc - Expects No Revenue for Q2 2025 - SEC Filing
07-10 04:52
Market-Moving News for July 8th
NDRA: 156% | ENDRA Life Sciences shares are trading higher after the company announced it will be granted a US patent titled "Radio Frequency Applicator". PROK: 158% | ProKidney shares are trading higher
07-08 19:32
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers ENDRA Life Sciences (NASDAQ:NDRA) stock increased by 50.4% to $5.2 dur...
07-08 05:06
ENDRA Life Sciences To Be Granted US Patent 'Radio Frequency Applicator.'
https://x.com/PatentAlerts4/status/1942312161243718143
07-08 04:18
ENDRA Life Sciences Announces That Its Ongoing Multisite Pilot Study Has Helped To Identify Several Product Enhancements To Further Improve The Performance Of Its TAEUS Liver System Against The Gold Standard, MRI
Refinements to probe configuration and proprietary algorithms are expected to drive substantial improvements in MRI-PDFF correlationENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer in imaging technologies for the early
06-16 20:11
ENDRA Life Sciences Unveils New Business Strategy
ENDRA Life Sciences ( ($NDRA) ) has issued an announcement. On June 11, 2025, E...
06-11 20:47
